

Index

a

AbsorbArray 57
 academic compound libraries 98, 99
 acyl imidazoles 10, 12, 363
 affinity selection mass spectroscopy (AS-MS) 356
 allosteric self-cleaving ribozymes 215
 amilorides 100, 102
 2-aminobenzimidazole viral translation inhibitor 337
 aminoglycosides 2, 22, 36, 53, 54, 58, 68, 72, 94–96, 108, 120, 127, 128, 130, 132, 133, 257, 258, 259, 271, 273
 5-aminoimidazole-4-carboxamide riboside 5'-triphosphate 207, 212, 371
 2-aminopurine (2-AP) 66, 68
 2-aminopyridine-3-carboxylic acid imidazolide (2A3) 10
 anti-Shine-Dalgarno sequence 214
 antibiotic drug development 210
 antibiotics 205–207
 antibiotic spectinomycin 22
 antisense molecules 2
 antisense oligonucleotide (ASO) 2, 41, 72, 74, 78, 93, 119, 127, 151, 183, 227–228, 274
 artificial ribonucleases 228
 atomic rotationally equivalent scorer (ARES) 337

automated ligand identification system (ALIS) 54, 356

Available Chemicals Directory (ACD) 370

b

base-pairing pattern 30
 benzimidazoles and purines 100, 101
 betacoronaviruses 269, 273
 binding site identification and target engagement 72
 biolayer interferometry (BLI) 63, 360
 biomolecules 31, 34, 51, 70, 71, 97, 130, 297, 367
 biosensors 64, 65, 204, 210–211
 bleomycin 229–231
 bleomycin-based direct degraders vs. RiboTACs 242
 bleomycin conjugates 142, 230–235, 242, 245
 bleomycin degraders 230, 245
 targeting oncogenic precursor microRNA 233–234
 targeting r(CCUG) repeat expansion that causes DM2 233
 targeting the r(CUG) repeat expansion that causes DM1 231–233
 branaplam lead generation 79–80
 brome mosaic virus tRNA-like structure (BMV TLS) 38

c

carmofur (1-hexylcarbamoyl-5-fluorouracil) 212, 213
catalytic enzyme-linked click chemistry assay (cat-ELCCA) 297, 356
cell-based RPI detection assays 300, 301
cellular target engagement methods 360–364
cellular thermal shift assays (CETSA) 360
chemical cross-linking and isolation by pull-down (Chem-CLIP, C-Chem-CLIP) 72, 136, 270, 360
chemical probes 10–12, 16, 19, 72, 97, 103, 106, 121
chemical similarity search algorithms 104
chromatin-associated regulatory RNAs (carRNAs) 325
cobalamin (vitamin B12) 2
coding and non-coding RNA 322, 328
cold shock domains (CSD) 290
commercial ligands 108–110
 academic libraries 98–99
 industrial libraries 98
covalent methods 72–74
Covid-19 pandemic 30, 273, 375
cryogenic electron microscopy (cryo-EM) 30, 367
cyanine dyes 68, 69

d

DEAD/DEAH box helicase domains 290
deep learning (DL) 40, 105, 368, 369
designer riboswitches 205, 213–214
Dicer 101, 122, 123, 125, 127, 128, 130, 131, 133, 134, 136, 139, 141, 233, 238, 240–243, 298, 358
dihydropteroate synthase 211
2,5-diketopiperazine (DKP) 261
diphenyl furan (DPF) 100, 103
direct mapping of RNA–RNA interactions 14–17

DNA-encoded libraries (DELs) 56–57, 139–140, 160, 242, 274, 356
double-stranded RNA (dsRNA) 96, 122, 123, 177, 236, 329
double-stranded RNA binding domains (dsRBD) 286–287
Dovitinib-RiboTAC 241, 243
drug discovery
 fragment-based 58–63
 history of 2
Duke RNA-Targeted Library (DRTL) 93
dynamic combinatorial chemistry 101, 103, 258
dystrophia myotonica protein kinase (*DMPK*) gene 229, 294

e

electrospray ionization mass spectrometry (ESI-MS) 51, 360
epitranscriptome 321–336
epitranscriptomics 4, 322, 325, 327, 330, 335
2-ethylquinoline 3-carboxamide moiety 259
eukaryotic expression platforms 214–216

f

first-generation RiboTACs targeting oncogenic miRNAs 236–239
flavin mononucleotide (FMN) 32, 56, 97, 207, 208–209, 364
fluorescence-based assays 66–69, 71, 297
fluorescent indicator displacement (FID) assays 67–69, 127, 359
Fomiversen 227
fragment-based drug design 138, 139
fragment-based drug discovery (FBDD) 58–63
fragment hit optimization 62–63
fragment library design 59
fragment screening method 59
frameshifting activity 254, 269

frameshift-stimulating element (FSE)
255, 256, 264
FSE RNA 256, 258–263, 274
functional assays 4, 49, 75–77, 357, 358,
364–367, 373–375

g

Gag and Gag-pol poly proteins 253,
256
geneticin 271, 273
genome-wide association studies (GWAS)
1, 8
G-quadruplexes (G4) 8, 156, 158, 365
Guanidinoneomycin B 257

h

hereditary transthyretin amyloidosis
(hATTR) 227
high resolution structures of RNA
cryo-EM 37–39
NMR spectroscopy 34–37
3D structure prediction and integrative
approaches 39–43
X-ray crystallography 31–34
hit optimization 49, 62–63, 76–78,
369–371
human immunodeficiency virus type 1
(HIV-1) 253, 256
N-hydroxypyridine-2(1*H*)-thione
(*N*-HPT) conjugates 229
N-hydroxypyridinethiones 229

i

immucillin-based compounds 212
industrial compound libraries 97, 98
inosine (I) 325, 328–330
internal ribosome entry sites (IRES) 8,
34, 54, 215, 335, 358
in vitro chemiluminescence-based assays
297–300
in vitro fluorescence-based assays 297
iron response elements (IRE) 8
isothermal titration calorimetry (ITC)
70, 358

k

Kennard–Stone algorithm 108
K homology (KH) domains 282, 289–290
knowledge-based vs. agnostic screening
49–50

l

lacZ (β -galactosidase) 211
LATS2 130, 132, 133
lead series
branaplam lead generation 79–80
hit optimization 77–78
risdiplam hit-to-lead 78–79
zotatifin lead generation 80
locked nucleic acids (LNAs) 2, 232
long non-coding RNAs (lncRNAs) 1, 120

m

macrolides 2, 95, 96, 120, 128, 176, 330
mass spectrometry 51–55, 76, 259, 274,
360
merafloxacin 269, 272, 273
messenger RNAs (mRNAs) 7, 75, 80,
120, 121, 203
metastasis associated lung
adenocarcinoma transcript 1
(MALAT-1) 33, 103
 N^6 -methyladenosine (m^6A) 325–330
N-methylation 260, 261
2-methylnicotinic acid imidazolide (NAI)
10
METTL3 325–327, 336
microarray screening 57–58
microRNAs (miRNAs)
biogenesis 122–123
cleavage properties 142–144
degradation and inhibit translation
121
discovery and identification of 121
RNA–protein interactions inhibition
140–142
with small-molecule RNA binders
pre- and pri-miRNA binders
125–140
tumor suppressor 124–125

- microscale thermophoresis (MST) 70, 359
- minimum free energy (MFE) 9, 368
- mRNA modifications
- inosine (I) 328–330
 - N*⁶-methyladenosine (m⁶A) 325–327
 - pseudouridine (Ψ) 327–328
 - roles of 322
- multivalent ligands 100, 103
- muscleblind-like 1 (MBNL1) splicing factor 229
- n**
- nafamostat 272–274
- naphthalene diimide (NDI) 101
- native riboswitch ligands 95–97
- natural ligands 108–110
- aminoglycosides 94–95
 - macrolides 96
 - native riboswitch ligands 96–97
 - tetracyclines 95–96
- 5-nitroisatoic anhydride (5NIA) 10
- non-coding RNAs (ncRNAs) 1, 3, 93, 119, 120, 122, 144, 274, 291, 292, 322, 325, 328, 330, 355
- nonmetal-based small molecules 228
- nuclear magnetic resonance (NMR)
- for fragment screening 60–61
 - spectroscopy 34–37
- nucleic acid ligand database (NALDB) 93, 374
- o**
- oncogenes 123, 141, 172, 176, 242, 326, 327, 365
- oncogenic pri-microRNAs 231
- oxazolidinones 100, 102, 107, 120
- p**
- peptide nucleic acids (PNAs) 2, 140
- phage display 63
- 1,10-phenanthroline-copper complexes 228
- phenotypic screens 3, 29, 49, 76, 78, 209, 356, 364
- photoaffinity evaluation of the RNA ligation-sequencing (PEARL-seq) 360, 361
- Piwi/Argonaute/Zwille (PAZ) domains 290
- posttranscriptional modifications of RNA 3, 31, 321, 335
- pre- and pri-miRNA binders
- DNA-encoded libraries (DEL) 139–140
 - fragment-based drug design 138–139
 - intracellular assays 125–127
 - specific ligands designs 131–138
 - target-based *in vitro* assays 127–131
- Programmed Ribosomal Frameshifting (PRF) 253–274
- protein-based genetic switches 214
- protein data bank (PDB) 29, 106, 367
- protein-interacting small molecules 323
- proteolysis-targeting chimeras (PROTACs) 162, 235
- proximity-induced nucleic acid degrader (PINAD) 363
- pseudotyped HIV 261
- pseudouridine (Ψ) 321, 325–331
- Pumilio (PUF) domains 290
- q**
- quantitative structure–activity relationship (QSAR) 102, 105, 107
- quinazoline 100, 101–102, 125
- quinoline derivatives 101
- r**
- r(CCUG)^{exp}-targeting bleomycin conjugate 230, 233
- reactivity-based RNA profiling (RBRP) 328, 331
- Resin Bound Dynamic Combinatorial Library (RBDCL) 258, 274
- respiratory syncytial virus 253, 254
- retroviruses 256

- Rev response element (RRE) 8, 70, 95
- RGG/RG domains 290
- rhodium (II) 9,10-phenanthrenequinone-diimine complexes 228
- ribocil-C 32, 97, 209
- RiboDock/rDOCK 370
- Ribonuclease L (RNase L) 236
- ribonuclease targeting chimeras (RiboTACs) 142, 235–244, 271, 363
- ribonucleoprotein complexes (RNPs) 2, 31, 281
- RiboSNAP 363
- ribosomal RNAs (rRNA) 2, 7, 22, 63, 69, 94, 120, 188, 207, 334–335
- riboswitches
 - antibiotics 205–207
 - barriers and future developments 210, 213
 - biosensors 210–211
 - in drug development 203–205
 - of a druggable 208
 - fluoride sensor illuminates agonists of fluoride toxicity 211
 - landscape of 203
 - in proof-of-principle demonstrations 209–210
 - SAH sensor reveals an inhibitor of SAH nucleosidase 212–213
 - small molecules targeting FMN 208–209
 - target 207–208
 - ZTP sensor identifies inhibitors of folate biosynthesis 211–212
- riboswitches in gene therapy
 - barriers and future developments 216–217
 - for designer 213–214
 - eukaryotic expression platforms 214–216
- risdiplam 180–186
 - Evrysdi® 183–186
 - hit-to-lead 78–79
- RNA-binding proteins (RBPs), regulation and dysregulation of 290–296
- RNA biopolymer 1, 3
- RNA folding problem 9
- RNA modifications 66, 321, 322, 327, 328, 335, 336
- RNA oligomerization-enabled cryo-EM via installing kissing-loops (ROCK) 38
- RNA–protein interactions 2
 - cell-based RNA–protein interaction screening 301–302
 - cell-based RPI detection assays 300–301
 - in vitro* chemiluminescence-based assays 297–300
 - in vitro* fluorescence-based assays 297
 - molecular basis
 - cold shock domains (CSD) 290
 - DEAD/DEAH box helicase domains 290
 - double-stranded RNA binding domains (dsRBD) 286–287
 - K homology (KH) domains 289–290
 - Piwi/Argonaute/Zwille (PAZ) domains 290
 - Pumilio (PUF) domains 290
 - RGG/RG domains 290
 - RNA recognition motifs (RRMs) 282–286
 - Sm domains 290
 - YT521-B homology domains 290
 - zinc finger (ZnF) domains 287–289
 - mRNA processing 294
- RNA recognition motifs (RRMs) 162, 282–286
- RNA sequencing 7, 39, 179, 188, 321, 331, 335, 375
- RNA structure
 - challenges in studying 8–9
 - dealing with heterogeneity 19–22
 - direct mapping of RNA–RNA interactions 14–16

- RNA structure (*contd.*)
- mapping spatially proximal nucleotides 17
 - prediction 355, 357
 - querying RNA–small molecule interactions with chemical probing 22
 - relevance in disease 8
 - structural interrogation of RNA nucleotides via chemical probing 10, 11
- RNA target classes 357, 358, 364
- RNA-targeted small molecule therapeutics 2
- RNA-Targeting Bioactive LiganD Database (R-BIND) 93
- RNA-targeting small molecules 324
- biophysical method 358–360
 - cellular target engagement methods 360–364
 - functional assays 364–367
 - deposition of 373–375
 - hit optimization 369–370
 - molecular dynamics simulations, machine learning, and AI tools 371–373
 - RNA structure prediction 367–369
- Rosetta-based FARFAR2 algorithm 39
- Rous sarcoma virus (RSV) 253
- rRNA modifications 322, 334–335
- S**
- S-adenosylhomocysteine (SAH) 207, 212
- SARS-CoV-1, 263, 268
- SARS-CoV-2 FSE 265, 267, 268, 273
- SARS-CoV-2 RNA 36, 41, 270, 271, 274
- screening and lead generation techniques, for RNA binders
- binding site identification and target engagement 72
 - fluorescence-based assays 66
 - functional assays 75
 - high-throughput screening (HTS) direct MS approaches 52–54
 - DNA-encoded libraries (DELs) 56–57
 - fragment-based drug discovery (FBDD) 58–63
 - indirect MS approaches 54–56
 - mass spectrometry 51–52
 - microarray screening 57–58
 - phage display 63
 - isothermal titration calorimetry (ITC) 70–72
 - knowledge-based vs. agnostic screening 49–50
 - microscale thermophoresis (MST) 70
 - phenotypic screens 76
 - screening funnel for 49, 50
 - surface plasmon resonance (SPR) 63
 - virtual screening 50–51
- Scripps Research Natural Products Discovery Center 94
- seed sequence 121
- selective 2'-hydroxyl acylation analyzed by primer extension (SHAPE) 10, 17, 266, 363
- self-cleaving ribozymes 215, 216
- severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) 102, 253, 357
- SHAPE-MaP data 266, 363, 368, 371, 373
- site-specific labeling assays (2-AP) 66–68
- slippery sequence 254, 256, 263–265, 270
- Sm domains 290
- small-angle X-ray/neutron scattering (SAXS/SANS) 42, 61
- small interfering RNAs (siRNAs) drug patisiran 227
- oligonucleotides 119
- small-molecule-based RiboTACs 239–242, 244
- small-molecule direct degraders 228–235
- small-molecule microarray (SMM) 33, 49, 131, 356, 365, 374
- Small Molecule Modulators of RNA (SMMRNA) 93, 336, 355

- small-molecule RNA targeting
 - chemical similarity search algorithms 104
 - commercial ligands 97–99, 108–110
 - machine-learning tools 105–106
 - natural ligands 94–97, 108–110
 - principal component analysis 104–105
 - QSAR 107
 - structure-based ligand design 106
 - synthetic ligands 99–100, 103, 108
- small molecules targeting FMN
 - riboswitches 208–209
- small molecules that degrade RNA
 - antisense oligonucleotide degraders 227–228
 - ribonuclease targeting chimeras (RiboTACs)
 - vs. bleomycin-based direct degraders 242
 - discovery of additional small molecule RNase L activators 242–243
 - first-generation RiboTACs targeting oncogenic miRNAs 236–239
 - Ribonuclease L (RNase L) 236
 - small-molecule-based 239–245
 - small molecule direct degraders
 - bleomycin conjugates 231
 - bleomycins 229–231
 - N*-hydroxypyridine-2(1*H*)-thione (*N*-HPT) Conjugates 229
 - small non-coding RNAs 120
 - spinal muscular atrophy (SMA) 2, 3, 74, 120, 151, 180–183
 - 5' splice site bulge repair 36
 - stemloops 254
 - structural interrogation of RNA
 - nucleotides via chemical probing 10–12
 - structure-based drug design (SBDD) 29, 77
 - sulfonamides 211, 212
 - surface plasmon resonance (SPR)
 - competition experiments 262
 - dealing with nonspecific interactions by 65–66
 - for fragment screening 61
 - small molecule-RNA interactions 65
 - survival motor neuron 1 (SMN1) gene 78
 - synthetic ligands 108–110
 - amiloride 102
 - benzimidazoles and purines 100–101
 - diphenyl furan (DPF) 103
 - multivalent ligands 103
 - naphthalenes 101–102
 - oxazolidinones 102
 - quinazoline 101–102
 - quinoline derivatives 101–102
- t**
 - Targapremir-18a 136
 - TargapremiR-210 134
 - target engagement of fragments 62
 - TAR RNA-binding protein (TRBP) 123, 124
 - target RNA or regulate RNA function 1
 - targeting viral enzymes 357
 - tetracycline repressor (TetR) protein 215
 - tetracycline-responsive Tet-ON/Tet-OFF systems 214
 - tetracyclines 95, 96
 - 3D structure prediction and integrative approaches 39–43
 - transfer RNA (tRNA) 29, 95, 120, 130, 240
 - modifications 323, 330–334
 - tumor suppressor miRNAs 124–125
 - two-dimensional combinatorial screening (2DCS) 130, 356
 - tyrosyl-tRNA synthetase (TyrRS) 38
- u**
 - untranslated regions (UTRs) 8, 292

V

virtual screening 33, 50–51, 61, 80, 102,
104, 106, 268, 370

W

Watson-Crick base-pairing rules 30, 227

X

X-ray crystallography 3, 30–34, 61, 63,
367

Y

YT521-B homology domains 290

Z

zinc finger (ZnF) domains 287–289

zotatifin lead generation 80

